KSF investigates Sanara MedTech sale to MiMedx over merger consideration

The law firm is reviewing whether Sanara shareholders are receiving adequate value under a deal offering $33.00 in cash and 0.4735 MiMedx shares per Sanara share.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.